세계의 진단 분야 인공지능(AI) 시장 규모, 점유율, 동향 분석 보고서 : 컴포넌트별, 진단별, 지역별 전망과 예측(2024-2031년)

The Global Artificial Intelligence in Diagnostics Market size is expected to reach $5.80 billion by 2031, rising at a market growth of 21.3% CAGR during the forecast period.

AI-powered diagnostic tools have significantly enhanced the accuracy and speed of detecting neurological conditions by analyzing brain scans, electroencephalograms (EEGs), and other medical imaging data. The ability of AI to identify subtle abnormalities in brain structures and predict disease progression has made it a crucial tool in neurological diagnostics. Additionally, the growing adoption of AI in neurosurgery planning and personalized treatment strategies has further fuelled the segment's expansion. Thus, the neurology segment acquired 23% revenue share in the market in 2023. This is driven by the increasing prevalence of neurological disorders such as Alzheimer's disease, Parkinson's disease, and stroke.

The major strategies followed by the market participants are Partnership as the key developmental strategy to keep pace with the changing demands of end users. For instance, In January, 2025, GE HealthCare Technologies, Inc. and Sutter Health form a seven-year strategic partnership to expand AI-powered imaging across California. The collaboration enhances diagnostic accuracy, patient access, and clinician efficiency while supporting workforce development and advancing service lines like cardiology, oncology, and neurosciences. Additionally, In January, 2025, DeepScribe and Flatiron Health partner to integrate AI-powered ambient documentation into OncoEMR(R), automating oncology clinical notes for 4,200+ providers. The AI reduces administrative burden, enhances workflow efficiency, and improves patient care by structuring clinical data and capturing key medical insights.

Based on the Analysis presented in the KBV Cardinal matrix; Microsoft Corporation is the forerunners in the Artificial Intelligence in Diagnostics Market. Companies such as NVIDIA Corporation and F. Hoffmann-La Roche Ltd. are some of the key innovators in Artificial Intelligence in Diagnostics Market. In March, 2024, Microsoft Corporation and NVIDIA expand collaboration to accelerate AI-driven healthcare innovation using Azure, DGX Cloud, and Clara. The partnership enhances medical imaging, drug discovery, and genomics, improving diagnostics and precision medicine while advancing clinical research through AI-powered cloud computing solutions.

COVID-19 Impact Analysis

The pandemic rapidly increased the adoption of AI-driven diagnostic tools to support overwhelmed healthcare systems. Hospitals and clinics relied more on AI-powered imaging technologies for faster detection of COVID-19 through CT scans and X-rays. Governments and private sectors invested heavily in AI-based diagnostics to improve early disease detection and management. Thus, the COVID-19 pandemic had a positive impact on the market.

Market Growth Factors

AI-powered diagnostic tools are revolutionizing healthcare by significantly improving accuracy and efficiency in disease detection. Traditional diagnostic methods often rely on manual interpretations by medical professionals, which can lead to errors and inconsistencies. AI-driven solutions, on the other hand, leverage machine learning algorithms and deep learning techniques to analyze complex medical data, enabling earlier and more precise diagnosis. Hence, the rising adoption of AI-powered diagnostic tools for improved accuracy and efficiency drives the market's growth.

Additionally, Integrating AI with cloud-based healthcare platforms is transforming how diagnostic data is stored, analyzed, and shared. Cloud computing enables healthcare institutions to centralize patient data, making it accessible to medical professionals across different locations. Integrating AI into cloud-based systems enhances the ability to process large volumes of medical images, lab results, and patient histories in real-time. In conclusion, increasing integration of AI with cloud-based healthcare platforms.

Market Restraining Factors

Despite AI's numerous advantages in diagnostics, its high implementation cost remains a significant barrier to adoption. Developing AI-powered diagnostic systems requires extensive investment in data infrastructure, machine learning models, and computing power. Healthcare providers, especially in developing regions, often struggle with budget constraints, making it difficult to afford these advanced solutions. The cost of acquiring AI diagnostic software, upgrading medical imaging equipment, and training staff further adds to the financial burden. In conclusion, AI-based diagnostic solutions' high initial investment and implementation costs are impeding the market's growth.

Component Outlook

Based on component, the market is characterized into software, hardware, and services. The hardware segment procured 35% revenue share in the market in 2023. The increasing need for AI-powered GPUs (graphics processing units), TPUs (tensor processing units), and edge computing devices to support complex diagnostic algorithms has significantly contributed to the growth of this segment.

Diagnosis Outlook

On the basis of diagnosis, the market is classified into cardiology, oncology, pathology, radiology, chest & lung, neurology, and others. The cardiology segment held 11% revenue share in the market in 2023. This is fuelled by the rising burden of cardiovascular diseases (CVDs) globally. AI has revolutionized cardiology diagnostics by enabling early detection and risk assessment of heart conditions such as coronary artery disease, arrhythmias, and heart failure. AI-driven ECG analysis, echocardiography interpretation, and cardiac imaging have enhanced diagnostic accuracy while reducing the workload on cardiologists.

Regional Outlook

Region-wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The Asia Pacific segment witnessed 20% revenue share in the market in 2023. This is driven by rapid technological advancements, growing healthcare expenditures, and increasing adoption of AI-driven healthcare solutions. Countries like China, Japan, India, and South Korea are witnessing a surge in AI-based diagnostics due to government initiatives promoting digital healthcare transformation.

Market Competition and Attributes

The Artificial Intelligence in Diagnostics Market is highly competitive, driven by rapid advancements in AI algorithms, increased healthcare digitalization, and growing demand for accurate, early disease detection. Competition is fueled by innovations in machine learning, deep learning, and cloud-based AI solutions. Key attributes influencing the market include precision, speed, scalability, and integration with existing healthcare systems. Regulatory approvals and data privacy concerns also shape competition. Companies focus on enhancing AI-powered diagnostics for multiple medical fields, ensuring efficiency, reliability, and cost-effectiveness.

Recent Strategies Deployed in the Market

• Jan-2025: GE HealthCare Technologies, Inc. and Sutter Health form a seven-year strategic partnership to expand AI-powered imaging across California. The collaboration enhances diagnostic accuracy, patient access, and clinician efficiency while supporting workforce development and advancing service lines like cardiology, oncology, and neurosciences.
• Jan-2025: DeepScribe and Flatiron Health partner to integrate AI-powered ambient documentation into OncoEMR(R), automating oncology clinical notes for 4,200+ providers. The AI reduces administrative burden, enhances workflow efficiency, and improves patient care by structuring clinical data and capturing key medical insights.
• Nov-2024: IBM Corporation and SiPH came into partnership to enhance Thailand's pathology diagnostics with AI-powered computational pathology, integrating workflows, image analysis, and automated cancer detection. The system improves accuracy, efficiency, and data security, advancing AI-driven diagnostics for better clinical care across Thailand and the ASEAN region.
• Nov-2024: GE HealthCare and RadNet's DeepHealth partnered to enhance AI-powered imaging with SmartTechnology(TM), starting with SmartMammo(TM) for breast cancer screening. The collaboration aims to improve diagnostic accuracy, workflow efficiency, and patient care, expanding AI adoption in radiology and medical imaging.
• Oct-2024: Microsoft expands AI in healthcare with Azure AI Studio models, Microsoft Fabric data solutions, and Copilot Studio agents. Innovations enhance diagnostics, streamline workflows, and support nursing. Responsible AI principles guide development, ensuring ethical, efficient healthcare advancements for improved patient outcomes.
• Mar-2024: F. Hoffmann-La Roche Ltd. partners with PathAI to develop AI-powered digital pathology algorithms for companion diagnostics. The algorithms, integrated into Roche's navify platform, enhance precision medicine by improving diagnostic accuracy and patient access to targeted treatments, accelerating AI adoption in digital pathology.

List of Key Companies Profiled

• Siemens Healthineers AG (Siemens AG)
• Zebra Technologies Corporation
• GE HealthCare Technologies, Inc.
• F. Hoffmann-La Roche Ltd.
• Microsoft Corporation
• NVIDIA Corporation
• IBM Corporation
• DeepScribe Inc.
• AliveCor, Inc.
• Digital Diagnostics, Inc. (3Derm Systems, Inc.)

Global Artificial Intelligence in Diagnostics Market Report Segmentation

By Component

• Software
• Hardware
• Services

By Diagnosis

• Neurology
• Radiology
• Chest & Lung
• Oncology
• Cardiology
• Pathology
• Other Diagnosis

By Geography

• North America
  • US
  • Canada
  • Mexico
  • Rest of North America
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Malaysia
  • Rest of Asia Pacific
• LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Table of Contents

Chapter 1. Market Scope & Methodology

• 1.1 Market Definition
• 1.2 Objectives
• 1.3 Market Scope
• 1.4 Segmentation
  • 1.4.1 Global Artificial Intelligence in Diagnostics Market, by Component
  • 1.4.2 Global Artificial Intelligence in Diagnostics Market, by Diagnosis
  • 1.4.3 Global Artificial Intelligence in Diagnostics Market, by Geography
• 1.5 Methodology for the research

Chapter 2. Market at a Glance

• 2.1 Key Highlights

Chapter 3. Market Overview

• 3.1 Introduction
  • 3.1.1 Overview
    • 3.1.1.1 Market Composition and Scenario
• 3.2 Key Factors Impacting the Market
  • 3.2.1 Market Drivers
  • 3.2.2 Market Restraints
  • 3.2.3 Market Opportunities
  • 3.2.4 Market Challenges

Chapter 4. Competition Analysis - Global

• 4.1 KBV Cardinal Matrix
• 4.2 Recent Industry Wide Strategic Developments
  • 4.2.1 Partnerships, Collaborations and Agreements
  • 4.2.2 Product Launches and Product Expansions
  • 4.2.3 Acquisition and Mergers
• 4.3 Market Share Analysis, 2023
• 4.4 Top Winning Strategies
  • 4.4.1 Key Leading Strategies: Percentage Distribution (2020-2024)
• 4.5 Porter Five Forces Analysis

Chapter 5. Global Artificial Intelligence in Diagnostics Market by Component

• 5.1 Global Software Market by Region
• 5.2 Global Hardware Market by Region
• 5.3 Global Services Market by Region

Chapter 6. Global Artificial Intelligence in Diagnostics Market by Diagnosis

• 6.1 Global Neurology Market by Region
• 6.2 Global Radiology Market by Region
• 6.3 Global Chest & Lung Market by Region
• 6.4 Global Oncology Market by Region
• 6.5 Global Cardiology Market by Region
• 6.6 Global Pathology Market by Region
• 6.7 Global Other Diagnosis Market by Region

Chapter 7. Global Artificial Intelligence in Diagnostics Market by Region

• 7.1 North America Artificial Intelligence in Diagnostics Market
  • 7.1.1 North America Artificial Intelligence in Diagnostics Market by Component
    • 7.1.1.1 North America Software Market by Country
    • 7.1.1.2 North America Hardware Market by Country
    • 7.1.1.3 North America Services Market by Country
  • 7.1.2 North America Artificial Intelligence in Diagnostics Market by Diagnosis
    • 7.1.2.1 North America Neurology Market by Country
    • 7.1.2.2 North America Radiology Market by Country
    • 7.1.2.3 North America Chest & Lung Market by Country
    • 7.1.2.4 North America Oncology Market by Country
    • 7.1.2.5 North America Cardiology Market by Country
    • 7.1.2.6 North America Pathology Market by Country
    • 7.1.2.7 North America Other Diagnosis Market by Country
  • 7.1.3 North America Artificial Intelligence in Diagnostics Market by Country
    • 7.1.3.1 US Artificial Intelligence in Diagnostics Market
      • 7.1.3.1.1 US Artificial Intelligence in Diagnostics Market by Component
      • 7.1.3.1.2 US Artificial Intelligence in Diagnostics Market by Diagnosis
    • 7.1.3.2 Canada Artificial Intelligence in Diagnostics Market
      • 7.1.3.2.1 Canada Artificial Intelligence in Diagnostics Market by Component
      • 7.1.3.2.2 Canada Artificial Intelligence in Diagnostics Market by Diagnosis
    • 7.1.3.3 Mexico Artificial Intelligence in Diagnostics Market
      • 7.1.3.3.1 Mexico Artificial Intelligence in Diagnostics Market by Component
      • 7.1.3.3.2 Mexico Artificial Intelligence in Diagnostics Market by Diagnosis
    • 7.1.3.4 Rest of North America Artificial Intelligence in Diagnostics Market
      • 7.1.3.4.1 Rest of North America Artificial Intelligence in Diagnostics Market by Component
      • 7.1.3.4.2 Rest of North America Artificial Intelligence in Diagnostics Market by Diagnosis
• 7.2 Europe Artificial Intelligence in Diagnostics Market
  • 7.2.1 Europe Artificial Intelligence in Diagnostics Market by Component
    • 7.2.1.1 Europe Software Market by Country
    • 7.2.1.2 Europe Hardware Market by Country
    • 7.2.1.3 Europe Services Market by Country
  • 7.2.2 Europe Artificial Intelligence in Diagnostics Market by Diagnosis
    • 7.2.2.1 Europe Neurology Market by Country
    • 7.2.2.2 Europe Radiology Market by Country
    • 7.2.2.3 Europe Chest & Lung Market by Country
    • 7.2.2.4 Europe Oncology Market by Country
    • 7.2.2.5 Europe Cardiology Market by Country
    • 7.2.2.6 Europe Pathology Market by Country
    • 7.2.2.7 Europe Other Diagnosis Market by Country
  • 7.2.3 Europe Artificial Intelligence in Diagnostics Market by Country
    • 7.2.3.1 Germany Artificial Intelligence in Diagnostics Market
      • 7.2.3.1.1 Germany Artificial Intelligence in Diagnostics Market by Component
      • 7.2.3.1.2 Germany Artificial Intelligence in Diagnostics Market by Diagnosis
    • 7.2.3.2 UK Artificial Intelligence in Diagnostics Market
      • 7.2.3.2.1 UK Artificial Intelligence in Diagnostics Market by Component
      • 7.2.3.2.2 UK Artificial Intelligence in Diagnostics Market by Diagnosis
    • 7.2.3.3 France Artificial Intelligence in Diagnostics Market
      • 7.2.3.3.1 France Artificial Intelligence in Diagnostics Market by Component
      • 7.2.3.3.2 France Artificial Intelligence in Diagnostics Market by Diagnosis
    • 7.2.3.4 Russia Artificial Intelligence in Diagnostics Market
      • 7.2.3.4.1 Russia Artificial Intelligence in Diagnostics Market by Component
      • 7.2.3.4.2 Russia Artificial Intelligence in Diagnostics Market by Diagnosis
    • 7.2.3.5 Spain Artificial Intelligence in Diagnostics Market
      • 7.2.3.5.1 Spain Artificial Intelligence in Diagnostics Market by Component
      • 7.2.3.5.2 Spain Artificial Intelligence in Diagnostics Market by Diagnosis
    • 7.2.3.6 Italy Artificial Intelligence in Diagnostics Market
      • 7.2.3.6.1 Italy Artificial Intelligence in Diagnostics Market by Component
      • 7.2.3.6.2 Italy Artificial Intelligence in Diagnostics Market by Diagnosis
    • 7.2.3.7 Rest of Europe Artificial Intelligence in Diagnostics Market
      • 7.2.3.7.1 Rest of Europe Artificial Intelligence in Diagnostics Market by Component
      • 7.2.3.7.2 Rest of Europe Artificial Intelligence in Diagnostics Market by Diagnosis
• 7.3 Asia Pacific Artificial Intelligence in Diagnostics Market
  • 7.3.1 Asia Pacific Artificial Intelligence in Diagnostics Market by Component
    • 7.3.1.1 Asia Pacific Software Market by Country
    • 7.3.1.2 Asia Pacific Hardware Market by Country
    • 7.3.1.3 Asia Pacific Services Market by Country
  • 7.3.2 Asia Pacific Artificial Intelligence in Diagnostics Market by Diagnosis
    • 7.3.2.1 Asia Pacific Neurology Market by Country
    • 7.3.2.2 Asia Pacific Radiology Market by Country
    • 7.3.2.3 Asia Pacific Chest & Lung Market by Country
    • 7.3.2.4 Asia Pacific Oncology Market by Country
    • 7.3.2.5 Asia Pacific Cardiology Market by Country
    • 7.3.2.6 Asia Pacific Pathology Market by Country
    • 7.3.2.7 Asia Pacific Other Diagnosis Market by Country
  • 7.3.3 Asia Pacific Artificial Intelligence in Diagnostics Market by Country
    • 7.3.3.1 China Artificial Intelligence in Diagnostics Market
      • 7.3.3.1.1 China Artificial Intelligence in Diagnostics Market by Component
      • 7.3.3.1.2 China Artificial Intelligence in Diagnostics Market by Diagnosis
    • 7.3.3.2 Japan Artificial Intelligence in Diagnostics Market
      • 7.3.3.2.1 Japan Artificial Intelligence in Diagnostics Market by Component
      • 7.3.3.2.2 Japan Artificial Intelligence in Diagnostics Market by Diagnosis
    • 7.3.3.3 India Artificial Intelligence in Diagnostics Market
      • 7.3.3.3.1 India Artificial Intelligence in Diagnostics Market by Component
      • 7.3.3.3.2 India Artificial Intelligence in Diagnostics Market by Diagnosis
    • 7.3.3.4 South Korea Artificial Intelligence in Diagnostics Market
      • 7.3.3.4.1 South Korea Artificial Intelligence in Diagnostics Market by Component
      • 7.3.3.4.2 South Korea Artificial Intelligence in Diagnostics Market by Diagnosis
    • 7.3.3.5 Australia Artificial Intelligence in Diagnostics Market
      • 7.3.3.5.1 Australia Artificial Intelligence in Diagnostics Market by Component
      • 7.3.3.5.2 Australia Artificial Intelligence in Diagnostics Market by Diagnosis
    • 7.3.3.6 Malaysia Artificial Intelligence in Diagnostics Market
      • 7.3.3.6.1 Malaysia Artificial Intelligence in Diagnostics Market by Component
      • 7.3.3.6.2 Malaysia Artificial Intelligence in Diagnostics Market by Diagnosis
    • 7.3.3.7 Rest of Asia Pacific Artificial Intelligence in Diagnostics Market
      • 7.3.3.7.1 Rest of Asia Pacific Artificial Intelligence in Diagnostics Market by Component
      • 7.3.3.7.2 Rest of Asia Pacific Artificial Intelligence in Diagnostics Market by Diagnosis
• 7.4 LAMEA Artificial Intelligence in Diagnostics Market
  • 7.4.1 LAMEA Artificial Intelligence in Diagnostics Market by Component
    • 7.4.1.1 LAMEA Software Market by Country
    • 7.4.1.2 LAMEA Hardware Market by Country
    • 7.4.1.3 LAMEA Services Market by Country
  • 7.4.2 LAMEA Artificial Intelligence in Diagnostics Market by Diagnosis
    • 7.4.2.1 LAMEA Neurology Market by Country
    • 7.4.2.2 LAMEA Radiology Market by Country
    • 7.4.2.3 LAMEA Chest & Lung Market by Country
    • 7.4.2.4 LAMEA Oncology Market by Country
    • 7.4.2.5 LAMEA Cardiology Market by Country
    • 7.4.2.6 LAMEA Pathology Market by Country
    • 7.4.2.7 LAMEA Other Diagnosis Market by Country
  • 7.4.3 LAMEA Artificial Intelligence in Diagnostics Market by Country
    • 7.4.3.1 Brazil Artificial Intelligence in Diagnostics Market
      • 7.4.3.1.1 Brazil Artificial Intelligence in Diagnostics Market by Component
      • 7.4.3.1.2 Brazil Artificial Intelligence in Diagnostics Market by Diagnosis
    • 7.4.3.2 Argentina Artificial Intelligence in Diagnostics Market
      • 7.4.3.2.1 Argentina Artificial Intelligence in Diagnostics Market by Component
      • 7.4.3.2.2 Argentina Artificial Intelligence in Diagnostics Market by Diagnosis
    • 7.4.3.3 UAE Artificial Intelligence in Diagnostics Market
      • 7.4.3.3.1 UAE Artificial Intelligence in Diagnostics Market by Component
      • 7.4.3.3.2 UAE Artificial Intelligence in Diagnostics Market by Diagnosis
    • 7.4.3.4 Saudi Arabia Artificial Intelligence in Diagnostics Market
      • 7.4.3.4.1 Saudi Arabia Artificial Intelligence in Diagnostics Market by Component
      • 7.4.3.4.2 Saudi Arabia Artificial Intelligence in Diagnostics Market by Diagnosis
    • 7.4.3.5 South Africa Artificial Intelligence in Diagnostics Market
      • 7.4.3.5.1 South Africa Artificial Intelligence in Diagnostics Market by Component
      • 7.4.3.5.2 South Africa Artificial Intelligence in Diagnostics Market by Diagnosis
    • 7.4.3.6 Nigeria Artificial Intelligence in Diagnostics Market
      • 7.4.3.6.1 Nigeria Artificial Intelligence in Diagnostics Market by Component
      • 7.4.3.6.2 Nigeria Artificial Intelligence in Diagnostics Market by Diagnosis
    • 7.4.3.7 Rest of LAMEA Artificial Intelligence in Diagnostics Market
      • 7.4.3.7.1 Rest of LAMEA Artificial Intelligence in Diagnostics Market by Component
      • 7.4.3.7.2 Rest of LAMEA Artificial Intelligence in Diagnostics Market by Diagnosis

Chapter 8. Company Profiles

• 8.1 Siemens Healthineers AG (Siemens AG)
  • 8.1.1 Company Overview
  • 8.1.2 Financial Analysis
  • 8.1.3 Segmental and Regional Analysis
  • 8.1.4 Research & Development Expense
  • 8.1.5 Recent strategies and developments:
    • 8.1.5.1 Partnerships, Collaborations, and Agreements:
    • 8.1.5.2 Acquisition and Mergers:
  • 8.1.6 SWOT Analysis
• 8.2 Zebra Technologies Corporation
  • 8.2.1 Company Overview
  • 8.2.2 Financial Analysis
  • 8.2.3 Segmental and Regional Analysis
  • 8.2.4 Research & Development Expenses
  • 8.2.5 Recent strategies and developments:
    • 8.2.5.1 Product Launches and Product Expansions:
  • 8.2.6 SWOT Analysis
• 8.3 GE HealthCare Technologies, Inc.
  • 8.3.1 Company Overview
  • 8.3.2 Financial Analysis
  • 8.3.3 Segmental and Regional Analysis
  • 8.3.4 Research & Development Expenses
  • 8.3.5 Recent strategies and developments:
    • 8.3.5.1 Partnerships, Collaborations, and Agreements:
  • 8.3.6 SWOT Analysis
• 8.4 F. Hoffmann-La Roche Ltd.
  • 8.4.1 Company Overview
  • 8.4.2 Financial Analysis
  • 8.4.3 Segmental and Regional Analysis
  • 8.4.4 Research & Development Expense
  • 8.4.5 Recent strategies and developments:
    • 8.4.5.1 Partnerships, Collaborations, and Agreements:
  • 8.4.6 SWOT Analysis
• 8.5 Microsoft Corporation
  • 8.5.1 Company Overview
  • 8.5.2 Financial Analysis
  • 8.5.3 Segmental and Regional Analysis
  • 8.5.4 Research & Development Expenses
  • 8.5.5 Recent strategies and developments:
    • 8.5.5.1 Partnerships, Collaborations, and Agreements:
    • 8.5.5.2 Product Launches and Product Expansions:
  • 8.5.6 SWOT Analysis
• 8.6 NVIDIA Corporation
  • 8.6.1 Company Overview
  • 8.6.2 Financial Analysis
  • 8.6.3 Segmental and Regional Analysis
  • 8.6.4 Research & Development Expenses
  • 8.6.5 SWOT Analysis
• 8.7 IBM Corporation
  • 8.7.1 Company Overview
  • 8.7.2 Financial Analysis
  • 8.7.3 Regional & Segmental Analysis
  • 8.7.4 Research & Development Expenses
  • 8.7.5 Recent strategies and developments:
    • 8.7.5.1 Partnerships, Collaborations, and Agreements:
  • 8.7.6 SWOT Analysis
• 8.8 DeepScribe Inc.
  • 8.8.1 Company Overview
  • 8.8.2 Recent strategies and developments:
    • 8.8.2.1 Partnerships, Collaborations, and Agreements:
• 8.9 AliveCor, Inc.
  • 8.9.1 Company Overview
  • 8.9.2 SWOT Analysis
• 8.10. Digital Diagnostics, Inc. (3Derm Systems, Inc.)
  • 8.10.1 Company Overview

Chapter 9. Winning Imperatives of Artificial Intelligence in Diagnostics Market